Country: United States
Language: English
Source: NLM (National Library of Medicine)
acyclovir (UNII: X4HES1O11F) (acyclovir - UNII:X4HES1O11F)
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc.
acyclovir
acyclovir 50 mg in 1 g
TOPICAL
PRESCRIPTION DRUG
Acyclovir ointment USP 5% is indicated in the management of initial genital herpes and in limited non- life-threatening mucocutaneous Herpes simplex virus infections in immunocompromised patients. Acyclovir ointment USP 5% is contraindicated in patients who develop hypersensitivity to the components of the formulation.
Each gram of Acyclovir Ointment USP 5% contains 50 mg acyclovir in a polyethylene glycol base. It is supplied as follows: Store at 20°-25°C (68°-77°F) [see USP Controlled Room Temperature]. Store in a dry place. 400214C R12/15 #285
Abbreviated New Drug Application
ACYCLOVIR- ACYCLOVIR OINTMENT E. FOUGERA & CO. A DIVISION OF FOUGERA PHARMACEUTICALS INC. ---------- FOUGERA ACYCLOVIR OINTMENT USP 5% FOR TOPICAL USE ONLY. Rx only PRESCRIBING INFORMATION DESCRIPTION Acyclovir is a synthetic nucleoside analogue active against herpes viruses. Acyclovir ointment USP 5% is a formulation for topical administration. Each gram of acyclovir ointment USP 5% contains 50 mg of acyclovir in a polyethylene glycol (PEG) base. Acyclovir is a white, crystalline powder with the molecular formula C H N O and a molecular weight of 225. The maximum solubility in water at 37°C is 2.5 mg/mL. The pka's of acyclovir are 2.27 and 9.25. The chemical name of acyclovir is 2-amino-1,9-dihydro-9-[(2-hydroxyethoxy)methyl]-6_H_- purin-6-one; it has the following structural formula: VIROLOGY MECHANISM OF ANTIVIRAL ACTION: Acyclovir is a synthetic purine nucleoside analogue with _in vitro_ and _in vivo_ inhibitory activity against herpes simplex virus types 1 (HSV-1), 2 (HSV-2), and varicella-zoster virus (VZV). The inhibitory activity of acyclovir is highly selective due to its affinity for the enzyme thymidine kinase (TK) encoded by HSV and VZV. This viral enzyme converts acyclovir into acyclovir monophosphate, a nucleotide analogue. The monophosphate is further converted into diphosphate by cellular guanylate kinase and into triphosphate by a number of cellular enzymes. _In vitro_, acyclovir triphosphate stops replication of herpes viral DNA. This is accomplished in 3 ways: 1) competitive inhibition of viral DNA polymerase, 2) incorporation into and termination of the growing viral DNA chain, and 3) inactivation of the viral DNA polymerase. The greater antiviral activity of acyclovir against HSV compared to VZV is due to its more efficient phosphorylation by the viral TK. ® 8 11 5 3 ANTIVIRAL ACTIVITIES: The quantitative relationship between the _in vitro_ susceptibility of herpes viruses to antivirals and the clinical response to therapy has not been established in humans, and virus sensitivity testing ha Read the complete document